BCL10 and diffuse large B-cell lymphoma: As new BTKis are developed, including the noncovalent inhibitor pirtobrutinib, further evaluation of key signaling pathways in relation to BCL10 mutations is necessary to understand potential therapeutic benefits for this subgroup of DLBCL.